These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16955683)

  • 1. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development.
    Kadow J; Wang HG; Lin PF
    Curr Opin Investig Drugs; 2006 Aug; 7(8):721-6. PubMed ID: 16955683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry.
    Da LT; Quan JM; Wu YD
    Proteins; 2011 Jun; 79(6):1810-9. PubMed ID: 21465559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
    Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
    Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A; Zhan CG
    J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.
    Veazey RS; Klasse PJ; Schader SM; Hu Q; Ketas TJ; Lu M; Marx PA; Dufour J; Colonno RJ; Shattock RJ; Springer MS; Moore JP
    Nature; 2005 Nov; 438(7064):99-102. PubMed ID: 16258536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W; Lu L; Li W; Jiang S
    Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions.
    Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH
    Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction.
    Williams DH; Adam F; Fenwick DR; Fok-Seang J; Gardner I; Hay D; Jaiessh R; Middleton DS; Mowbray CE; Parkinson T; Perros M; Pickford C; Platts M; Randall A; Siddle D; Stephenson PT; Tran TD; Vuong H
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5246-9. PubMed ID: 19620004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
    Teixeira C; Serradji N; Maurel F; Barbault F
    Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
    Ketas TJ; Schader SM; Zurita J; Teo E; Polonis V; Lu M; Klasse PJ; Moore JP
    Virology; 2007 Aug; 364(2):431-40. PubMed ID: 17428517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and optimisation of potent gp120-CD4 inhibitors.
    Tran TD; Adam FM; Calo F; Fenwick DR; Fok-Seang J; Gardner I; Hay DA; Perros M; Rawal J; Middleton DS; Parkinson T; Pickford C; Platts M; Randall A; Stephenson PT; Vuong H; Williams DH
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5250-5. PubMed ID: 19632839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A conserved molecular action of native and recombinant Epap-1 in inhibition of HIV-1 gp120 mediated viral entry.
    Roda Rani KP; Pelluru D; Kondapi AK
    Arch Biochem Biophys; 2006 Dec; 456(1):79-92. PubMed ID: 17078922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
    Vermeire K; Schols D
    J Antimicrob Chemother; 2005 Aug; 56(2):270-2. PubMed ID: 15980096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.
    Meanwell NA; Wallace OB; Fang H; Wang H; Deshpande M; Wang T; Yin Z; Zhang Z; Pearce BC; James J; Yeung KS; Qiu Z; Kim Wright JJ; Yang Z; Zadjura L; Tweedie DL; Yeola S; Zhao F; Ranadive S; Robinson BA; Gong YF; Wang HG; Spicer TP; Blair WS; Shi PY; Colonno RJ; Lin PF
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1977-81. PubMed ID: 19251416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
    Liu T; Huang B; Zhan P; De Clercq E; Liu X
    Eur J Med Chem; 2014 Oct; 86():481-90. PubMed ID: 25203778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
    Williamson MP; McCormick TG; Nance CL; Shearer WT
    J Allergy Clin Immunol; 2006 Dec; 118(6):1369-74. PubMed ID: 17157668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120.
    Tan H; Rader AJ
    Proteins; 2009 Mar; 74(4):881-94. PubMed ID: 18704932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression.
    Nabatov AA; van Montfort T; Geijtenbeek TB; Pollakis G; Paxton WA
    FEBS J; 2006 Nov; 273(21):4944-58. PubMed ID: 17010165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
    Repits J; Sterjovski J; Badia-Martinez D; Mild M; Gray L; Churchill MJ; Purcell DF; Karlsson A; Albert J; Fenyö EM; Achour A; Gorry PR; Jansson M
    Virology; 2008 Sep; 379(1):125-34. PubMed ID: 18672260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.